GoAI
Get started
MediWound Ltd. logo

MediWound Ltd.

MDWD

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$13.21

+$0.095 · +0.72%

Aug 21, 4:00 PM ET

MDWD company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

39

Expensive

Momentum

30

Weakening

Sentiment

57

Mixed

Risk resilience

47

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

Industry
Biotechnology
Sector
Healthcare
Headquarters
IL
CEO
Ofer Gonen
Listed since
Mar 20, 2014
Employees
121

Market position

Day range

Current $13.21

52-week range

Current $13.21

Open
$13.20
Previous close
$13.115
Volume
79.83K
1× average
Average volume
79.85K
Average daily volume
Market cap
169.69M USD
Beta
0.16
Market reference 1
50-day average
$14.2539
-7.32% below average
200-day average
$16.5087
-19.98% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
213.36M USD
P/E (TTM)
-8.26×
P/B (TTM)
4.77×
P/S (TTM)
14.3×
EV / EBITDA
-9.94×
Earnings yield
-11.37%
Free cash flow yield
-9.54%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
15.46%
Operating margin
-267.86%
Net margin
-170.10%
Return on equity
-54.73%
Return on assets
-27.68%
Return on invested capital
-41.75%

Financial health

Debt / equity
0.27×
Current ratio
2.33×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends70%-10%-90%-169%Gross margin, FY2021: 36.91%Gross margin, FY2022: 49.69%Gross margin, FY2023: 19.15%Gross margin, FY2024: 13.03%Gross margin, FY2025: 19.19%Operating margin, FY2021: -47.22%Operating margin, FY2022: -28.91%Operating margin, FY2023: -82.96%Operating margin, FY2024: -95.85%Operating margin, FY2025: -149.06%Net margin, FY2021: -57.03%Net margin, FY2022: -73.97%Net margin, FY2023: -35.94%Net margin, FY2024: -149.46%Net margin, FY2025: -140.80%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 36.91%. Gross margin FY2022 49.69%. Gross margin FY2023 19.15%. Gross margin FY2024 13.03%. Gross margin FY2025 19.19%. Operating margin FY2021 -47.22%. Operating margin FY2022 -28.91%. Operating margin FY2023 -82.96%. Operating margin FY2024 -95.85%. Operating margin FY2025 -149.06%. Net margin FY2021 -57.03%. Net margin FY2022 -73.97%. Net margin FY2023 -35.94%. Net margin FY2024 -149.46%. Net margin FY2025 -140.80%.

Income trends

Revenue

16.96M USD-16.14%

Operating income

−25.28M USD-30.43%

Net income

−23.88M USD+20.99%
Income trends across reported periods32.17M USD9.48M USD−13.21M USD−35.9M USDRevenue, FY2021: 23.76M USDRevenue, FY2022: 26.5M USDRevenue, FY2023: 18.69M USDRevenue, FY2024: 20.22M USDRevenue, FY2025: 16.96M USDOperating income, FY2021: −11.22M USDOperating income, FY2022: −7.66M USDOperating income, FY2023: −15.5M USDOperating income, FY2024: −19.38M USDOperating income, FY2025: −25.28M USDNet income, FY2021: −13.55M USDNet income, FY2022: −19.6M USDNet income, FY2023: −6.72M USDNet income, FY2024: −30.22M USDNet income, FY2025: −23.88M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 23.76M USD. Revenue FY2022 26.5M USD. Revenue FY2023 18.69M USD. Revenue FY2024 20.22M USD. Revenue FY2025 16.96M USD. Operating income FY2021 −11.22M USD. Operating income FY2022 −7.66M USD. Operating income FY2023 −15.5M USD. Operating income FY2024 −19.38M USD. Operating income FY2025 −25.28M USD. Net income FY2021 −13.55M USD. Net income FY2022 −19.6M USD. Net income FY2023 −6.72M USD. Net income FY2024 −30.22M USD. Net income FY2025 −23.88M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue16.96M USD20.22M USD18.69M USD26.5M USD23.76M USD
Cost of goods sold13.71M USD17.59M USD15.11M USD13.33M USD14.99M USD
Gross profit3.25M USD2.63M USD3.58M USD13.17M USD8.77M USD
Research and development14.32M USD8.88M USD7.47M USD10.18M USD10.26M USD
Selling, general, and administrative13.93M USD12.91M USD11.38M USD10.37M USD9.45M USD
Operating expenses28.53M USD22.02M USD19.08M USD20.83M USD19.99M USD
Interest income1.86M USD2.05M USD2.34M USD270K USD11K USD
Interest expense663K USD561K USD335K USD162K USD167K USD
Depreciation and amortization1.86M USD1.48M USD1.3M USD1.27M USD1.24M USD
Operating income−25.28M USD−19.38M USD−15.5M USD−7.66M USD−11.22M USD
Net income−23.88M USD−30.22M USD−6.72M USD−19.6M USD−13.55M USD

Company facts updated Aug 24, 2026.

MDWD peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding MDWD

Funds reporting this stock among their holdings, ordered by reported position size.

iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
3.11M
Weight
0.00%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
ARK Israel Innovative Technology ETF logoARK Israel Innovative Technology ETFIZRL
Market value
1.92M
Weight
1.46%
AUM
136.9M USD
Expense ratio
0.49%
Price / 1D
$29.04+0.87%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
1.19M
Weight
0.01%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
814.16K
Weight
0.00%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
454.02K
Weight
0.03%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
iShares Russell 3000 ETF logoiShares Russell 3000 ETFIWV
Market value
174.22K
Weight
0.00%
AUM
20.23B USD
Expense ratio
0.20%
Price / 1D
$436.47+0.43%
Vanguard Russell 2000 Growth ETF logoVanguard Russell 2000 Growth ETFVTWG
Market value
147.55K
Weight
0.01%
AUM
1.7B USD
Expense ratio
0.06%
Price / 1D
$282.73+1.21%
Invesco NASDAQ Future Gen 200 ETF logoInvesco NASDAQ Future Gen 200 ETFQQQS
Market value
102.47K
Weight
0.45%
AUM
22.98M USD
Expense ratio
0.20%
Price / 1D
$45.0826+1.10%

Continue in GoAI

Research MDWD

research.disclaimer